Showing results 4 to 6 of 6
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
Treatment intensification with Dipeptidylpeptidase-4 inhibitor, insulin, or Thiazolidinediones and risks of cardiovascular diseases and all-cause mortality in patients on metformin-sulfonylurea dual therapy Proceeding/Conference:14th International Symposium on Healthy Aging, 2019 | 2019 | ||
Triple Therapy with Dpp4 Inhibitor, Insulin, or Thiazolidinediones and Risks of Cardiovascular Diseases and All-Cause Mortality in Patients with Failed Metformin-SU Therapy Proceeding/Conference:Journal of Hypertension | 2019 | ||
Weight loss, cardiovascular diseases and all-cause mortality of overweight/obese patients with type 2 diabetes mellitus initiating sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1A) Proceeding/Conference:International Congress on Obesity and Metabolic Syndrome & Asia-Oceania Conference on Obesity (ICOMES & AOCO), 2019 | 2019 |